ライフサイエンスコーパス: pegfilgrastim

1 for the detection of methionine oxidation in pegfilgrastim.

2 and active in CRPC and requires dosing with pegfilgrastim.

3 the combination of docetaxel, lapatinib, and pegfilgrastim.

4 taneous injection of either normal saline or pegfilgrastim.

5 cular mass of 40074.64 Da was determined for pegfilgrastim.

6 A single subcutaneous injection of pegfilgrastim 100 micro g/kg produced a sustained serum

7 ) for six cycles with scheduled subcutaneous pegfilgrastim 6 mg on day 2 of each cycle.

8 00 mg/m(2)) for 4 cycles every 2 weeks (with pegfilgrastim 6 mg on day 2) followed by paclitaxel (80

9 Patients received pegfilgrastim 6 mg subcutaneous (SQ) on day 2 of each cy

10 Pegfilgrastim 6 mg subcutaneous injection was administer

11 g/m2 and ixabepilone 35 mg/m2 every 21 days, pegfilgrastim 6 mg subcutaneously day 2, and continuous

12 were randomly assigned to either placebo or pegfilgrastim 6 mg subcutaneously on day 2 of each 21-da

13 d by P (175 mg/m(2)) x 4 every 2-weekly with pegfilgrastim (6 mg on day 2) + T x1 year.

14 of this study was to evaluate the effects of pegfilgrastim, a long-acting granulocyte colony-stimulat

15 lute quantification of oxidation variants of pegfilgrastim, a poly(ethylene glycol) modified recombin

16 s of dose-dense chemotherapy and the ease of pegfilgrastim administration.

17 Pegfilgrastim and darbepoetin alfa are effective and saf

18 The incidence of grade 4 neutropenia in the pegfilgrastim and filgrastim groups was 69% and 68%, res

19 Results Pegfilgrastim and filgrastim were similar for all effica

20 roblem that may result in discontinuation of pegfilgrastim and lead to less effective chemotherapy do

21 time was similar between patients receiving pegfilgrastim and patients who initially received placeb

22 famide (10 g/m(2) over 4 days with mesna and pegfilgrastim) as first-line treatment.

23 CONCLUSION A single dose of pegfilgrastim at 100 microg/kg administered once per che

24 Finally, an expired pegfilgrastim batch was analyzed as a a real biopharmace

25 The protocol was amended to include pegfilgrastim because of dose-limiting toxicity (neutrop

26 ony stimulating factor (PEGylated rhG-CSF or pegfilgrastim), by electrospray ionization-mass spectrom

27 Patients receiving pegfilgrastim, compared with patients receiving placebo,

28 6:1 randomization ratio to receive a single pegfilgrastim dose of 100 microg/kg (n = 38) or daily fi

29 protracted neutropenia and had higher median pegfilgrastim exposure than older children.

30 receiving 1 dose of docetaxel and adjunctive pegfilgrastim, follow-up (18)F-FDG PET/CT (scan 2).

31 ible and received three cycles of AMVAC with pegfilgrastim followed by radical cystectomy with lymph

32 standardized uptake value) was higher in the pegfilgrastim group 1 d after injection (mean +/- SD, 8.

33 ile neutropenia were converted to open-label pegfilgrastim in subsequent cycles.

34 Interventions for pegfilgrastim-induced bone pain are needed.

35 Pegfilgrastim-induced bone pain is a significant clinica

36 ve in reducing the incidence and severity of pegfilgrastim-induced bone pain.

37 t incidence, severity, or ability to prevent pegfilgrastim-induced bone pain.

38 nd pharmacokinetics of a single subcutaneous pegfilgrastim injection with daily subcutaneous filgrast

39 In both the animal model and humans, pegfilgrastim markedly increased bone marrow uptake of (

40 ions in (18)F-FDG biodistribution induced by pegfilgrastim must be considered when one is evaluating

41 eight patients received placebo (n = 465) or pegfilgrastim (n = 463).

42 ndard epirubicin) or every 2 weeks with 6 mg pegfilgrastim on day 2 of each cycle (accelerated epirub

43 All patients received pegfilgrastim on day 2 of each cycle and aspirin prophyl

44 , the highest dose levels were repeated with pegfilgrastim on day 2 of each cycle.

45 nts randomly assigned to receive one dose of pegfilgrastim or daily filgrastim after chemotherapy.

46 A single injection of pegfilgrastim per chemotherapy cycle provided neutrophil

47 between two treatment strategies of primary pegfilgrastim prophylaxis.

48 Once-per-cycle administration of pegfilgrastim simplifies the management of neutropenia a

49 Pegfilgrastim stressed with 1.0% hydrogen peroxide serve

50 ficacy and safety of neoadjuvant ddMVAC with pegfilgrastim support in muscle-invasive urothelial canc

51 ffects of a single subcutaneous injection of pegfilgrastim (sustained-duration filgrastim) 100 micro

52 We evaluated the efficacy of pegfilgrastim to reduce the incidence of febrile neutrop

53 C-CSF use increased from 13.2% to 67.9%, and pegfilgrastim use increased from 4.1% to 83.6%.

54 nefit from dose-dense chemotherapy, limiting pegfilgrastim use would combat the increasing costs of c

55 dose level for lapatinib and docetaxel with pegfilgrastim was 1,250 mg (once daily) and 75 mg/m(2) (

56 In 2002, pegfilgrastim was approved by the US Food and Drug Admin

57 Pegfilgrastim was generally well tolerated and safe, and

58 e maximum tolerated dose in combination with pegfilgrastim was not exceeded.

59 Pegfilgrastim was safe and well tolerated in this patien

60 combination of docetaxel and lapatinib with pegfilgrastim was well tolerated.

61 First and subsequent cycle use of pegfilgrastim with a moderately myelosuppressive chemoth